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Objective: To compare the incidence of adverse events between active and placebo arms
of randomized clinical trials in depressive children and adolescents (C&A) with antidepres-
sant treatments, in order to look for similarities in both groups that allow to establish a
possible nocebo effect.
Methods: Systematic search strategy (January 1974–March 2013) in electronic databases,
conference abstracts, and reference list of systematic reviews and included studies to iden-
tify parallel randomized placebo-controlled trials of antidepressants in C&A (<19 years) with
major depressive disorder, and one or more interventions of any orally administered anti-
depressant.The pooled adverse events were calculated based on a fixed-effect model and
statistical analysis involved the risk ratio (RR) of adverse events, with 95% confidence
intervals (95% CI).
Results: Sixteen studies were included in the review, of which seven studies with a sam-
ple of 1911 patients had data to include in the meta-analysis. There was similar risk for the
incidence of adverse events between non-active and active group (global RR 1.04, 95% CI:
0.97–1.11).
Conclusion: Depressive C&A allocated to placebo or active group had similar risk to
develop adverse events. These similarities in both groups are attributed to the nocebo
effect. It is of note that defining “nocebo” effects is challenging in clinical populations
because adverse effects may be attributed to the intervention or may be manifestation of
the disease itself. The inclusion of a no-treatment arm may be warranted. Nocebo effects
are likely when adverse events of placebo mimic the adverse events of active treatment,
as was the case here.
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INTRODUCTION
The use of antidepressants for children and adolescents (C&A) is
still a matter of debate due to questionable efficacy and risk of
adverse events. The efficacy of these medications appears to be
influenced by patient such as function indication, age, chronicity,
and study characteristics (Bridge et al., 2007). Negative effects of
placebo – nocebo effects (NE) – occur in 25% of patients (Hauser
et al., 2012a). NE can be induced by negative expectation, sugges-
tion,and previous experiences,and are influenced by psychological
characteristics as well as therapy situation and context (Wells and
Kaptchuk, 2012; Ciaramella et al., 2013), which can influence the
expectations of patient, the clinician, and other involved parties.
Systematic reviews have proved the efficacy of antidepressants
compared to placebo in adults with major depressive disorder
(MDD) (Undurraga and Baldessarini, 2012). The adverse effect
profiles between different therapy groups such as selective sero-
tonin receptor inhibitors (SSRIs) and tricycle antidepressants
(TCAs) are prone to systematic expectation influences in both
patients and investigators (Gracely et al., 1985; Mora et al., 2011).
In C&A, the effectiveness of antidepressant drugs is a controversial
topic (Hazell, 2009) since there is an important incidence of AE
and suicide-related events using SSRIs. Hence, these drugs have
received a “black-box” warning by the Food and Drug Admin-
istration and the Medicines and Healthcare products Regulatory
Agency cautions physicians on their use in C&A (Hetrick et al.,
2012).
Defining “nocebo” effects is challenging in clinical popula-
tions. An adverse effect (such as dry mouth, loose stool, frequent
Frontiers in Behavioral Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 375 | 1
Rojas-Mirquez et al. Nocebo effect in depressed youth
urinations, or insomnia) may be a “nocebo” or it may be somatic
manifestations of the disease itself. Additionally, factors related
with NE have been identified in the pediatric population that
may lead to confusion, such as divergent behaviors of the dis-
ease and parental/cultural influence (Fernandes et al., 2008). The
nocebo profile seems to parallel drug side effects in adults (Bram-
billa et al., 2005). In the context of a randomized clinical trial, in
order to assess a true placebo or nocebo effect, the non-active drug
should ideally be compared to a no-treatment group. True placebo
response would be symptom improvements in the non-active
treatment arm that go above and beyond spontaneous remis-
sion in the no-treatment group. Likewise, true nocebo responses
are adverse effects that go above and beyond symptoms in the
no-treatment group. An unfortunate methodological fact is that
very few RCT’s include such a no-treatment group. Thus, we call
adverse events in non-active arms “nocebo-like effects,” with the
caveat that such effects may in part be spontaneous symptoms
and manifestations of disease rather than true NE. This meta-
analysis aims to compare the incidence of adverse events between
active and placebo arms of randomized clinical trials in depressive
C&A with SSRI, TCA, and SSNRI treatments, in order to look for
similarities in adverse effect profiles in active and placebo arms.
MATERIALS AND METHODS
We conducted a systematic review and meta-analysis of antide-
pressant RCTs in C&A with MDD to describe and compare the
AE in placebo and treatment arms. This study was conducted
according to the recommendations of the Cochrane Collaboration
(Higgins and Green, 2011a) and the PRISMA Statement (Moher
et al., 2009), PROSPERO code CRD42013004638 (Rojas-Mirquez
et al., 2013).
ELIGIBILITY CRITERIA
Studies
We included parallel, placebo-controlled RCTs of antidepressants
in depressed C&A conducted between 1/1/1974 and 3/31/2013.
Other types of RCTs and those that assessed other condition
simultaneously were excluded. No language restrictions were
imposed.
Participants
Female and male children (6–12 years) (National Center for
Biotechnology Information, 2013a) and/or adolescents (13–
18 years) (National Center for Biotechnology Information, 2013b)
with MDD diagnosed with specific criteria. There were no prefer-
ences in any other demographic characteristic of participants.
Interventions
RCTs that compared placebo with one or more orally adminis-
tered antidepressant drugs. There was no restriction of dosage,
frequency, or duration of the treatment.
Outcomes
The primary outcome measure was the incidence of AE in placebo
and treatment groups looking for similarities in both groups that
allow to establish a possible NE. The secondary outcome was the
efficacy of antidepressant treatment for C&A with MDD.
INFORMATION SOURCES AND SEARCH STRATEGY
We designed a search strategy for RCTs published in PubMed,
CENTRAL, EMBASE, and BIREME. The search strategy was spe-
cific for each database and includes a combination of the medical
subject headings and free text terms (see Table 1).Clinicaltrials.gov
for RCTs and biosis.org for conference abstracts were used to find
additional studies, as well as reference lists of selected articles,
reviews, and previous meta-analyses.
STUDY SELECTION
Two investigators (Johanna Carolina Rojas-Mirquez, Milton Jose
Max Rodriguez-Zuñiga) independently screened the titles and
abstracts to determine the potential usefulness of the articles. Eli-
gibility criteria were applied to the full text articles during the final
selection. We resolved disagreements by consensus and by a third
reviewer (Herney Andres Garcia-Perdomo).
DATA COLLECTION PROCESS
All data were collected independently by two authors using a stan-
dardized data extraction sheet in Epi-Info™ 7.0 software (Centers
for Disease Control and Prevention, CDC, Atlanta, GA, USA).
An independent reviewer (Francisco Javier Bonilla-Escobar) con-
firmed all data entries and checked at least twice for completeness
and accuracy.
DATA ITEMS
We extracted variables related with characteristics of the article,
study design, patient’s data, and AE. All types of adverse events
were included since authors of included clinical trials did not pro-
vide detail on the nature of adverse event reported. When data
were not available, this was noted.
RISK OF BIAS IN INDIVIDUAL STUDIES AND ACROSS THEM
The Cochrane Collaboration risk of bias tool (Higgins et al.,
2011; Sterne and Moher, 2011) was used independently by two
researchers (Johanna Carolina Rojas-Mirquez, Milton Jose Max
Rodriguez-Zuñiga). Disagreements were solved by consensus. A
“Risk of bias table” and a risk of bias summary were edited using
Review Manager Software Version 5.1® (RevMan) to illustrate the
judgments for each study.
QUALITY ASSESSMENT OF AE
A Cochrane tool to assess quality and report of AE was used to eval-
uate the methodology that researchers used as well as the quality
of the reports for published studies (Higgins and Green, 2011b).
SYNTHESIS OF RESULTS
The risk ratio (RR) was the effect measured of the primary out-
come, with 95% confidence intervals (95% CI). The efficacy of
antidepressant treatment was defined as the standardized mean
difference (SMD) between baseline and post-treatment values on
depression scales. AE were only evaluated over the course of the
intervention.
Included trials were characterized with descriptive statistics and
median with 25th–75th percentiles (p25–p75) such as central ten-
dency and dispersion measures. Quantitative data were analyzed
with non-parametric tests, due to their non-normal distribution
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Table 1 | Study and patients characteristics of RCTs included into the analysis.
Author Therapy
group
FDA
appr-
oval
Therapy
duration
(days)
Popul-
ation
Sample
size
Patients
on
placebo
(n)
Patients
on
therapy
group
(n)
Drop-
outs
(n)
Efficacy
outcome
measure
tool
Baseline
measure
(mean)
Postreatment
(mean)
∆ Efficacy Assess-
ment
strategy
for AEs
AEs
placebo
(n)
AEs
therapy
group
(n)
Plac-
ebo
The-
rapy
Plac-
ebo
The-
rapy
Plac-
ebo
The-
rapy
Berard et al. (2006) Paroxetine No 84 Adole-
scents
286 99 187 90 MADRS 25.9 25.9 13.1 12.3 12.8 13.6 Structured 56 119
Kye et al. (1996) Amitriptyline No 56 Adole-
scents
31 13 18 9 HAM-D 13.2 12 8.8 8 4.4 4 Structured NR NR
Geller et al. (1992) Nortriptyline No 56 Children 60 29 31 10 CDRS-R 49.6 49.9 32 32.9 17.6 17 Structured NR NR
Keller et al. (2001) (1): Paroxetine No 56 Adole-
scents
275 87 (1): 93 86 HAM-D 18.97 (1): 18.98 9.88 (1): 8.24 9.09 (1): 10.74 Observations NR NR
(2): Imipramine (2): 95 (2): 18.11 (2): 9.2 (2): 8.91
Wagner et al. (2004) Citalopram No 56 Both 178 85 93 36 CDRS-R 57.8 58.8 41.8 37.8 Combination NR NR
GlaxoSmithKline
(2011)
Paroxetine No 56 Both 56 27 29 7 CDRS-R NR NR −11.9 −16.5 11.9 16.5 Structured 9 9
Emslie et al. (2009) Escitalopram No 56 Adole-
scents
316 158 158 53 CDRS-R 56 57.6 37.2 35.5 18.8 22.1 Combination 118 121
Simeon et al. (1990) Paroxetine No 49 Adole-
scents
40 20 20 10 HAM-D NR NR NR NR Not stated NR NR
Almeida-Montes
(2005)
Fluoxetine Yes 30 Both 23 11 12 7 DSR-S NR NR NR NR Structured NR NR
Wagner et al. (2006) Escitalopram No 56 Both 268 136 132 51 CDRS-R 56.6 54.5 36.4 32.6 20.2 Combination 90 90
Eli Lilly and
Company (2013a)
(1): Duloxetine No 70 Both 337 103 (1): 117 72 CDRS-R 60.2 (1): 59.2 35.9 (1): 34.9 24.3 (1): 24.3 Structured 68 (1): 70
(2): Fluoxetine (2): 117 (2): 58.8 (2): 35.1 (2): 23.7 (2): 72
Kutcher et al. (1994) Desipramine No 42 Adole-
scents
60 30 30 18 CDRS-R 23.77 22.63 13.42 12.68 Structured NR NR
Wagner et al. (2003) Sertraline No 70 Both 376 187 189 77 CDRS-R 64.6 64.3 38.77 34.06 Combination NR NR
Emslie et al. (2002) Fluoxetine yes 56 Both 219 110 109 61 CDRS-R 55.1 57.1 40.2 35.1 14.9 22 Combination NR NR
Eli Lilly and
Company (2013b)
(1): Duloxetine
60 mg
No 70 Both 463 122 (1): 108 138 CDRS-R 58.2 (1): 59.3 36.6 (1): 35.4 21.6 (1): 23.9 Structured 71 (1): 76
(2): Duloxetine
30 mg
(2): 116 (2): 11 (2): NR (2): NR (2): 66
(3): Fluoxetine
30 mg
(3): 117 (3): 57.9 (3): NR (3): NR (3): 69
Emslie et al. (2006) Paroxetine No 56 Both 206 102 104 54 CDRS-R 62.6 60.7 39.2 38.1 23.4 22.6 Spontaneous
reports
62 71
(1), Arm 1; (2), Arm 2; (3), Arm 3.
FDA, Food and Drug Administration; n, number of patients; ∆, difference between baseline and post-treatment values on depression scales; AEs, adverse events; MADRS, Montgomery–Asberg Depression Rating
Scale; HAM-D, Hamilton Depression Rating Scale; CDRS-R, Children’s Depression Rating Scale-Revised; DSR-S, Depression Self-Rating Scale; NR, no report; RCTs, randomized clinical trials.
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assessed by Shapiro–Wilk method. The confidence level was 95%,
and these analyses were performed on Stata13® (College Station,
TX, USA: StataCorp LP).
Heterogeneity between trials was assessed through the I 2 sta-
tistic, which indicates the percentage of variation in the effect
size estimate attributable to heterogeneity rather than sampling
error (I 2 value greater or equal to 50% represents heterogene-
ity) (Higgins et al., 2003). The pooled AE and efficacy on both
groups were calculated based on a fixed and random effect model,
respectively, taking into account the heterogeneity of the studies.
If studies show heterogeneity, results are based on a random effect
model, and if studies are homogeneous, their results are based on a
fixed-effect model (Bollen and Brand, 2010). Results are reported
as forest plots showing the effect size of all the included studies
with 95% CI.
Subgroup analysis
They were performed on the basis of age category (C&A) and drug
category (SSRIs, NRIs, and TCAs) through RevMan®.
Sensitivity analysis
The relative RR was used for all primary analyses, and the Mantel–
Haenszel random effects model was used for sensitivity analysis
(Der-Simonian and Laird, 1986). We undertook the sensitivity
analysis based on the exclusion of each one of the trials, as well as
the unpublished and the smallest trials.
MISSING DATA
All data were used in the systematic review. Corresponding authors
were contacted in the cases of missing data. The pooled available
data were used for the meta-analysis.
RESULTS
STUDY SELECTION
We identified 1018 studies. The final sample size meeting all inclu-
sion criteria consisted of 16 studies performed in C&A with MDD,
whereof seven studies met the criteria for quantitative analy-
sis. Selection process and characteristics of excluded studies are
detailed in Figure 1.
STUDY CHARACTERISTICS
We analyzed 16 studies with a total of 3194 patients. Of those, 1319
were randomized to non-active and 1875 to an active group. The
study sample sizes ranged from 23 to 463 patients. Thirteen were
published in journals, while the rest were studies available on a
clinical trial register for unpublished data (see Table 1).
In the age group analysis, nine out of 16 studies were carried out
in both age groups (C&A), six trials were performed just in ado-
lescents and one trial included only children (Geller et al., 1992).
313 children and 678 adolescents were included to non-active and
319 and 869 to an active drug, with no difference in proportions
of children allocated to non-active or to an active arm by pharma-
cologic group (p= 0.17); however, there were significantly more
adolescents in the SSNRI trials than in TCA trials (p= 0.002). The
median age for all included participants was 13 (10–16), and it
was similar for participants in the non-active and active group
(p= 0.67).
All studies included both genders. In the 14 trials that reported
the participants’ gender (3389 patients), 54% were female. Of
those, 40% were allocated in non-active and 60% in an active
group (p= 0.68). There was a significant difference between the
proportion of males and females by pharmacologic group, with a
higher proportion of males in the TCA studies and a majority of
females in SSRI and SNRI studies (p= 0.0074).
Thirteen out of 16 trials assessed a SSRI in at least one of its
arms, two a SNRI and four a TCA. Not including non-active arms,
13 studies had one active intervention arm, two trials had two
active intervention arms (Keller et al., 2001; Eli Lilly and Com-
pany, 2013a), and one trial had three arms (Eli Lilly and Company,
2013b). There were 10 different drugs used in the active arms,
with five paroxetine trials (Simeon et al., 1990; Keller et al., 2001;
Berard et al., 2006; Emslie et al., 2006; GlaxoSmithKline, 2011),
four fluoxetine (Emslie et al., 2002; Almeida-Montes, 2005; Eli
Lilly and Company, 2013a,b), three duloxetine (Eli Lilly and Com-
pany, 2013a,b), two escitalopram trials (Wagner et al., 2006; Emslie
et al., 2009), and single studies of imipramine (Keller et al., 2001),
amitriptyline (Kye et al., 1996), nortriptyline (Geller et al., 1992),
citalopram (Wagner et al., 2004), desipramine (Kutcher et al.,
1994), and sertraline (Wagner et al., 2003).
A pharmaceutical company sponsored 13 out of the 16 trials,
one was sponsored by the National Institute of Mental Health
(Geller et al., 1992), one by the Nordic Merrell Dow Research and
the Ontario Mental Health Foundation (Kutcher et al., 1994), and
one did not provide information about the sponsor (Simeon et al.,
1990).
The median intervention period had 56 (56–63) days of expo-
sure to a drug, with 56 (30–84) days to SSRI, 70 (70–70) to
SNRI, and 56 (42–56) days to TCAs, without significant differences
(p= 0.11).
All trials used more than one tool for depression diagnosis
with 12 out of 16 trials used the DSM-IV (Diagnostic and Sta-
tistical Manual of Mental Disorders, Fourth Edition), 10 using
the Children Depression Scales-Revised (CDS-R), and 8 using
the Kiddie-Schedule for affective disorders and schizophrenia for
school-age children (K-SADS-P). All the trials assessed the effi-
cacy of the drug as the primary outcome. The most frequent
primary outcome measure tool used was CDRS-R in 11 trials,
while three used Hamilton Depression Rating Scale, one used
the Montgomery and Asberg Depression Rating Scale (MADRS)
(Berard et al., 2006), and the Depression Self-Rating Scale (DSR-S),
respectively (Almeida-Montes, 2005).
The total number of dropouts was 779, whereof 63% were allo-
cated in the active group. The total rate of discontinuation was 22%
with median discontinuation rate for placebo and active groups
of 20% (11–38) and 25% (14–43), respectively. There were no sta-
tistically significant difference (p= 0.06), nor by pharmacologic
group (p= 0.93).
RISK OF BIAS WITHIN AND ACROSS STUDIES
The risk of bias summary was performed to show how each study
was assessed for each domain (see Figure S1 in Supplementary
Material). Around 90% of the trials had high risk of attrition bias,
related to withdrawals and dropouts. All trials had an unclear risk
of selection bias, associated to the lack of information about the
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FIGURE 1 | Flow diagram on numbers of publications screened and included. AEs, adverse events.
allocation concealment process. Nearly 85% of trials had low risk
of other bias, considering the comparable condition of the arms
in their baseline characteristics. In all, 75% of studies were unclear
about the masking method, although all trials were defined as
double blinded (Figure 2).
QUALITY ASSESSMENT ON CONDUCT AND REPORT OF AE
Cochrane’s tool was applied to 13 published studies, which pro-
vided the necessary information in order to do a judgment
regarding the conduct and report of adverse events. The most
frequent AE evaluation strategy was structured assessment (eight
out of 16), using weekly scales, checklist, and questionnaires. The
combination of assessment methods (five out of 16) consisted
in spontaneous reports, physical examination of patients in each
visit, and observation by investigators, while two trials used either
spontaneous report of symptoms by the patient or observation
and physical examination by the care professional in charge. One
trial did not provide information on its assessment strategy for
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FIGURE 2 | Risk of bias across all included studies.
AE (Simeon et al., 1990). Of the seven studies included in the
quantitative analysis, four used a structured method, either weekly
AE monitoring or systematic assessment of AE, two used a com-
bination that included spontaneous report and observation by
investigators and one included study used the spontaneous report
by patients (see Table S1 in Supplementary Material) (Emslie et al.,
2006).
RESULTS OF INDIVIDUAL STUDIES AND SYNTHESIS OF RESULTS
The most frequents AE were headache (RR 1.22, 95% CI 0.87–
1.71), nausea (RR 1.88, 95% CI 1.44–2.45), dizziness (RR 2.04,
95% CI 1.41–2.96), abdominal pain (RR 1.18, 95% CI 0.81–1.72),
vomiting (RR 1.58, 95% CI 1.07–2.34), insomnia (RR 2.16, 95%
CI 1.42–3.27), somnolence (RR 1.51, 95% CI 0.78–2.92), and
decrease appetite (RR 1.58, 95% CI 0.95–2.61); these are reported
according to the rank of frequency of AE in placebo groups. Of
the above symptoms, nausea, vomiting, insomnia, and dizziness
had more significant risk to be present in patients taking anti-
depressants, compared to non-active treatment (see Figure S2 in
Supplementary Material).
Nocebo effects
The pooled effect estimate of NE was calculated with seven out
of 16 trials that reported the number of patients who presented
adverse events for each intervention group (1911 patients, 39%
were in non-active group). The heterogeneity for the adverse
effects’ RR was low (I 2= 0%), and there was no increased risk in
developing them in patients allocated to an active drug and those
allocated to non-active (RR 1.04, 95% CI 0.97–1.11). All the trials
had similar risk to present AE in patients taking an active drug or
taking placebo (Figure 3A). Table S2 in Supplementary Material
shows the five most frequent AE for each one of the pharmaco-
logical group of antidepressants, and those that presented higher
risk of development in non-active groups. Headache and nausea
were the symptoms presented more frequently in patients allo-
cated in non-active groups compared with any active treatment
group, with proportions of 14 and 7%, respectively.
SSRIs trials
Following headache and nausea, nasopharyngitis, abdominal pain,
and vomiting were the most common AE presented by patients
of non-active groups (see Table S2 in Supplementary Material).
Nasopharyngitis was a NE, with RR 0.94 (95% CI 0.64–1.39).
SNRIs trials
Following headache and nausea, abdominal pain upper, dizziness,
and somnolence were the most common AE presented by patients
of non-active groups (see Table S2 in Supplementary Material).
Abdominal pain was a NE with a RR 0.89 (95% CI 0.54–1.44).
TCAs trials
Following headache and nausea, dizziness, dry mouth, and respi-
ratory disorder were the most common AE presented by patients
of non-active groups (see Table S2 in Supplementary Material).
Headache and respiratory disorder were NEs, with RR 0.96 (95%
CI 0.66–1.39) and 0.58 (95% CI 0.23–1.45), respectively. Of note,
dizziness and dry mouth were significantly more common in the
active treatment groups.
Efficacy analysis
Ten out of 16 trials reported measures baseline and post-treatment
for each intervention group. In all, 1123 patients in the active
group and 828 in non-active group were included to calculate the
pooled estimate of antidepressants efficacy. The heterogeneity for
efficacy analysis was high (I 2= 96%), and there was a mild, but
statistically significant reduction in the depression score scales in
patients taking an antidepressant drug as compared to placebo,
with the estimates in the same direction (SMD −1.79, 95% CI
−2.92 to−0.66) (Figure 4A).
ADDITIONAL ANALYSIS
Subgroup analysis
In the analysis of pharmacologic drug group and risk of AE, there
were no significant differences seen among a SSRI drug (RR 1.04,
95% CI 0.97–1.12) or a SNRI drug (RR 1.01, 95% CI 0.88–1.15)
in comparison to non-active drug (Figure 3B). For patients taking
a TCA and SNRI, there was no significant change in the depres-
sion severity scales compared to placebo (SMD TA 0.18, 95% CI
−0.09 to −0.45; SMD SNRI −1.24, 95% CI −3.49 to −1.01). On
the other hand, there was a significant reduction in the depression
severity scales in patients taking a SSRI drug (SMD−2.11, 95% CI
−3.25 to−0.96) (Figure 4B).
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FIGURE 3 | Nocebo effect of antidepressant treatment. (A) Forest plot
of comparison: antidepressant treatment versus placebo; outcome:
adverse events. (B) Forest plot of subgroup analysis: adverse event risk of
placebo versus SSRI or SNRI. CI, confidence interval; SSRI, selective
serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake
inhibitors.
The subgroup analysis by age was only done for efficacy. We
included four trials that were conducted solely in adolescents, and
one trial that involved only children. There was no difference in the
decrease of the depression scales in children or in adolescents who
took an active drug in comparison to non-active, although ado-
lescents showed a better improvement (SMD adolescents −1.47,
95% CI −3.01 to −0.07; SMD children 0.06, 95% CI −5.77 to
−6.97) (Figure 4C).
Sensitivity analysis
For sensitivity analysis, we stepwise removed each trial in the
AE analysis; neither of them exerted a significant change in the
recalculated overall RR.
DISCUSSION
NOCEBO EFFECT
Despite higher representation in placebo, both patients allocated
to non-active and experimental groups had similar risk to develop
AE. This has already been reported by other authors in pain-related
trials (Amanzio et al., 2009; Hauser et al., 2012b; Mitsikostas et al.,
2012) and clinical trials of depression in adults (Rief et al., 2009;
Hegerl et al., 2010).
It should be noted that no RCTs included a no-treatment arm.
As such, it is not possible to define whether adverse events are
true NE, or manifestations of the disease itself. However, there are
several indications that the reported adverse events are indeed
of “nocebo” type. In previous systematic reviews on TCA tri-
als, it has been shown that the most frequent nocebo symptoms
were headache, nausea, dizziness, dry mouth palpitations, and
tremor (Hazell and Mirzaie, 2013). In the current analysis of mul-
tiple types of antidepressants, we found the two most frequent
instances of NE to be headache and nausea, where only nausea
showed a significantly increased risk in placebo arms. The placebo
group of TCAs trials was more likely to present dizziness and
dry mouth, SNRIs upper abdominal pain and dizziness, and SSRIs
nasopharyngitis and abdominal pain. The placebo groups in TCAs
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A
B
C
FIGURE 4 | Efficacy of antidepressant treatment. (A) Forest plot of
comparison: antidepressant versus placebo, outcome: efficacy. (B) Forest
plot of subgroup analysis: efficacy by pharmacologic group of
antidepressant versus placebo, and (C) Forest plot of subgroup analysis:
efficacy by age group in antidepressant versus placebo. SD, standard
difference; CI, confidence interval; TCA, tricyclic antidepressants; SSRI,
selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine
reuptake inhibitors.
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trials had the highest rate of NE, with nearly 33% of patients hav-
ing stronger sedating and cholinergic profile, while placebo groups
in the SSRI trials had the lowest rates. This is in accordance with
the concept that the nocebo effect profile reflects those effects
of active group (Gracely et al., 1985; Amanzio et al., 2009; Mit-
sikostas et al., 2012). Although our major findings about nocebo
effect are similar than those of pain-related trials, it is imperative
to highlight that a likely reason of these findings is insufficient
descriptions, quality, and reliability AE assessment methods in the
included randomized clinical trials.
Headache is commonly seen as a NE that affects compliance
and adherence to treatments (Colloca and Miller, 2011; Mit-
sikostas et al., 2012). It is frequently presented in adolescents
with depression (Nardi et al., 2013); however, reports show that
healthy adolescents present headaches with prevalence of 11.9–
29.1% (Ghandour et al., 2004; Bohman et al., 2012). Here, we
found an 18% incidence of headaches among subjects assigned
to placebo and 23% among patients assigned to an active drug,
leading to reconsider its status as a real nocebo effect.
Many infection-related AE showed (non-significantly) higher
frequency in the non-active group. This phenomenon might be
explained by random chance or be related to the association
between depression and altered immune function (Jones and
Thomsen, 2013). Depression-induced immune system alterations,
rather than nocebo, is a possible explanation.
Nocebo effect has been widely attributed to three important
factors: expectations (Benedetti and Amanzio, 2013; Faasse and
Petrie, 2013), suggestions (van Laarhoven et al., 2011), and condi-
tioning (Hauser et al., 2012b; Data-Franco and Berk, 2013). It can
be seen by the nocebo influence of clinicians, parents’ expectations,
or patients sharing their experiences in the waiting room during
visits. Moreover, anxiety-related symptoms of depression, soma-
tization, or generalized psychological distress might influence the
development of NE (Rogers, 2003). Bavbek et al. (2014) suggest
that higher education and the patient history of hypersensitivity
to medications increase the risk of nocebo responses. Less experi-
enced physicians also appear to contribute to the nocebo response
(Ashraf et al., 2014). Women may have a slightly larger nocebo
response than men (Casper et al., 2001), as may homozygous car-
riers of the Val158 variant of the catechol-O-methyltransferase
(COMT) gene (Val158met) (Wendt et al., 2014).
As suggested by Bingel (2014), some possible strategies to
reduce NE include (a) optimizing treatment expectations and
expectations of adverse effects, (b) a balanced presentations of risks
and benefits, (c) teaching coping skills, (d) providing evidence-
based information as opposed to alarmist web-forums, (e) better
drug leaflet information, (f) hidden tapering in of medications, (g)
pretreatment with drugs with low adverse effects, (h) video clips
with patient examples coping well with adverse effects, (i) authen-
tic and empathic patient–physician communication, (j) adequate
information regarding disease, diagnoses, treatments, and adverse
effects, (k) systematic feedback to patients, (l) pedagogical teaching
(such as proactive check-back questions) to prevent negative biases
and misunderstandings, and (m) adequately addressing patients’
anxieties, concerns, and expectations.
It is important to consider these factors in clinical and research
practice in order to control this phenomenon. As the “therapeutic
ritual” play an important role for the placebo and nocebo mecha-
nism (Benedetti, 2012), physicians should cultivate positive rein-
forcement and continuous support to ensure patients’ adherence
to the procedure and minimize the likelihood of nocebo (Benedetti
and Amanzio, 2011).
Some authors have made some recommendations to reduce
the nocebo effect in RCT’s. For instance, Amanzio (2011) have
proposed the use of the natural history group as a “third arm”
in pain trials, allowing the comparison of placebo groups with
non-treated groups in order to seek for specific nocebo symp-
toms. Moreover, Cohen (2014) has proposed new approaches in
the informed consent of trials that aim to avoid the nocebo influ-
ence due the advertisement of potential adverse events. Although
these options could address the NE in clinical trials, this may be
unfeasible due the critical ethical component of failing to inform
a patient clearly about the procedures, known risks, and conse-
quences, as well as the fact that untreated patients suffer from a
serious condition.
EFFICACY OF ANTIDEPRESSANTS
Currently, fluoxetine is the only antidepressant supported by the
FDA for treatment of MDD in children aged 8 years and older.
Also,our analysis indicates that fluoxetine has higher improvement
on depression scales over placebo. However, the clinical status of
fluoxetine use on pediatric patients remains in constant discus-
sion due the incidence of suicidal ideation and suicidal attempts
shown in previous clinical trials (Hetrick et al., 2012). In this order,
the current recommendation is a constant monitoring of AE in
patients taking SSRIs (Silva and Sampaio, 2011).
The efficacy analysis of antidepressants in depressive C&A
when compared with placebo shows a mild statistically significant
reduction in the depression scales used to determine the effect of
treatment, which stood out in the Emslie et al. (2002) RCT (active
drug was fluoxetine) due its marked efficacy over placebo (mean
difference of −7.10 with 95% CI−11.69 to−2.51). Furthermore,
the subgroup analysis of pharmacologic drug efficacy of antide-
pressants indicated that only SSRIs did significantly better than
placebo,compared with SNRIs and TCAs. In particular, the current
study findings indicate that fluoxetine has higher improvement on
depression scales over placebo, consistent with the general use of
fluoxetine as the primary treatment choice for C&A depression
(Raz, 2006).
Regarding the treatment of the depressive population below
19 years old, there remains a discussion concerning the potential
risk-benefit of SSRI treatment. Symptoms such as suicide ideation
and suicide attempt may be considered as an inherent AE of these
medications, a nocebo effect, or even due to the nature of the dis-
ease. Furthermore, Silva and Sampaio (2011) have proposed that
these AE could be product of an underlying bipolar disorder in
C&A undergoing treatment for MDD. In this order, the current
recommendation is a constant monitoring of AE in patients taking
these SSRIs.
An important concern that arises due to the lack of a well-
known safe and effective treatment for C&A with MDD is the high
rate of off-label prescription of antidepressants in this population.
Compared with patients aged between 19 and 24 years, Czaja and
Valuck (2012) found that patients under 18 had a higher number of
Frontiers in Behavioral Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 375 | 9
Rojas-Mirquez et al. Nocebo effect in depressed youth
prescriptions without strong support from the FDA. Antidepres-
sants in C&A is less effective than the response obtained in adult
patients, both in terms of treatment response and AE profile.
Assessing the heterogeneity of the clinical trials
The heterogeneity assessment showed homogeneous results for
the pooled effect size of AE (I 2= 0, Figure 3). The explanation
is that risks for AE were similar across the trials. In contrast, high
heterogeneity was demonstrated in the efficacy analysis (I 2= 96%,
Figure 4A). Heterogeneity for the efficacy analysis was related with
the high variance of the pooled effect size in the improvement of
depression scales: in TCA trials, placebo did better, while SSRIs did
better than placebo.
We showed robustness of the results with the sensitivity analy-
sis. After the exclusion of any trial from the analysis, the overall
result did not modify significantly, neither of AE for efficacy
analysis.
LIMITATIONS
Our study has several limitations: first, attempts to obtain miss-
ing data were unsuccessful. Second, there was an inconsistency on
adverse events’ assessment and report across the studies, with less
than half of trials reporting the number of patients who presented
AE, and without information about severity and about a potential
relation between the symptom and the treatment, which consti-
tuted a constraint to perform the quantitative analysis for adverse
events. Moreover, studies do not specify the type of AE assessment
method used according to the nature of the symptom presented
and studies used multiple methods for AE assessment, likely lead-
ing to different results. For instance, the structured approach
was the most frequent assessment method for AE in RCTs, using
scales, checklists, and questionnaires that led to only look for a
specific set of AE. Others used a combination of methods, includ-
ing clinician observation and patient spontaneous report, which
might lead to a biased overestimation or underestimation of AE
and decrease the quality of the adverse events reported. Third,
the high proportion of unclear and high risk of bias within and
across studies is concerning. Lack of information regarding the
randomization, blinding process, and few details about the allo-
cation concealment sequence might increase the probability of
foreseeing the allocation group of participants and skew the pri-
mary outcome of the included trials (Schulz and Grimes, 2002).
Finally, there were high rates of dropouts and withdrawals leading
to a high risk of attrition bias, but none of the included stud-
ies described completely the frequency and reasons of dropouts
in each intervention group, which did not allow to perform a
deep analysis of dropouts in those patients allocated to active or
control arms.
CONCLUSION
The frequency of adverse effects did not differ between active
treatment and placebo arms; moreover, the benefits of depres-
sive treatment are mild and vary between studies. Our findings
highlight the similar risk of presenting AE for patients receiving
placebo compared to antidepressant treatment, indicative of (a)
the relative safety of antidepressants and (b) possible NE.
IMPLICATIONS FOR PRACTICE
Analysis of antidepressants’ efficacy for C&A showed an improve-
ment of depression scales in patients taking SSRIs. Although SSRIs
are the first line of pharmacological treatment for depressive C&A,
there still remains a gap of knowledge regarding the safety profile
due to suicidal-related attempts. For this reason, it is impera-
tive to keep a constant monitoring of adverse events in patients
undergoing SSRI treatment.
Our findings highlight the similar risk of presenting AE for
patients receiving placebo compared to antidepressant treatment.
It is of note that in clinical context, as well as in the research arena,
there are some aspects to identify and address in depressive C&A
in order to decrease the NE. The influence of parents’ expectations,
anxiety-related symptoms of depression, and “therapeutic rituals”
might influence the nocebo phenomenon.
IMPLICATIONS FOR RESEARCH
The influence of NE over the adverse events’ profile of antidepres-
sants still remains doubtful, and it may be necessary to conduct
further studies that allow understanding of the nature of nocebo
phenomenon, perhaps also with no-treatment arms. For future
studies, it is necessary to implement standardized methods to
assess and report AE in RCTs of antidepressants in C&A.
It is imperative to clearly report methodological aspects of clini-
cal trials in order to reduce the risk of bias related to randomization
process, blinding of personnel and participants, allocation con-
cealment method, and the report of dropouts and reasons for
them. Strengthening these efforts should assure readers a com-
plete understanding of the methodology and the quality of the
results.
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